CDNA vs VRTX
CareDx, Inc vs Vertex Pharmaceuticals — AI-powered side-by-side comparison
VS
VRTX
Vertex Pharmaceuticals
66
Buy
| Metric | CDNA | VRTX |
|---|
| AI Score |
59
|
66
|
| Price |
$47.20
|
$529.70
|
| P/E Ratio |
21.95×
|
30.58×
|
| ROE |
-7.0%
|
21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
70.6%
|
86.0%
|
| Debt / Equity |
0.05×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
74.3
|
80.4
|
| Beta |
2.419
|
0.305
|
| Expected Upside |
—
|
+1.5%
|
AI Committee View
Current Innellis committee reasoning for CDNA versus VRTX.
VRTX leads by 7 points.
VRTX scores 66/100 (Buy) versus CDNA at 59/100 (Buy).
CDNA Committee View
75% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 50.3% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- RSI at 74 is in overbought territory — Technical
- Weekly RSI at 86 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 50.3% signals elevated volatility — Risk
VRTX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 29.0 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- RSI at 80 is in overbought territory — Technical